Background: COPD is primarily the disease of the lungs; nevertheless, multiple systemic manifestations including poor sleep quality and sleep disturbances have been linked to this illness. Administration of sedative hypnotics is not recommended in COPD patients, as these drugs suppress the ventilatory response and exacerbate sleep-related disorders. Melatonin is an alternative medication that has been widely used to treat sleep disturbances caused by aging and other specific conditions. We aimed to investigate the efficacy of melatonin administration in improvement of sleep quality in COPD patients.
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition characterized by irreversible limitation of airflow (1) . COPD imposes a significant burden; in 2000, the World Health Organization (WHO) estimated that 2.47 million people died from COPD worldwide. It is projected that by 2020, COPD will become the third leading cause of death (2) . In the United Kingdom, COPD is the leading cause of chronic respiratory disease (3) . The main risk factor for developing COPD is smoking; others include air pollution, occupational TANAFFOS exposure to chemical substances and dusts, poor nutritional status, alcohol consumption and alpha-1-antitrypsin deficiency (4) .
COPD primarily affects the lungs; however, various systemic complications including pulmonary hypertension (5, 6) , cor pulmonale (7, 8) , weight loss (9,10), insulin resistance (11) , systemic inflammation (12) , depression (13, 14) , and sleep disturbances (15) have been linked to COPD.
An important and common systemic consequence of COPD is sleep disturbances characterized by insomnia and poor sleep quality. A rich body of subjective and objective evidence exist describing sleep disturbances in COPD patients (16) (17) (18) (19) . Sleep disorders and insomnia negatively affect the quality of life of COPD patients (20) .
Administration of conventional sedative-hypnotic drugs (e.g. benzodiazepines) is not recommended in patients with respiratory failure, as these drugs may suppress ventilatory response and exacerbate sleep-related breathing disorders (21) .
Melatonin, an endogenous hormone synthesized and secreted into the systemic circulation and cerebrospinal fluid by the pineal gland (22) , is believed to play a cardinal role in regulating the circadian rhythm and sleeping during the night. Melatonin has been widely used to treat sleep disturbances and insomnias caused by aging and other specific pathologic conditions (23) (24) (25) .
Given the principal role of melatonin in regulation of somnolence, we aimed to evaluate the efficacy of exogenous melatonin administration in improving sleep quality in COPD patients.
MATERIALS AND METHODS
In order to evaluate the effect of melatonin therapy on sleep quality of COPD patients, a randomized, double- manifests poor sleep quality with a sensitivity of 89.6% and specificity of 86.5% (27) . Since patients with the history of sedative-hypnotic medication use were excluded from the study, score of the sixth component was set as zero for all patients.
Secondary outcomes were daytime sleepiness and lung function and oxygenation. Daytime sleepiness was evaluated by Epworth Sleepiness Scale (ESS), a subjective questionnaire designed to determine the level of daytime sleepiness. Patients are asked to rate the probability of sleeping or dozing on a scale of increasing probability from 0 (none) to 3 (high probability) for eight different situations (sitting and reading, watching TV, sitting inactive in a public place, being a passenger in a vehicle for an hour without a break, lying down to rest in the afternoon whenever circumstances permit, sitting and talking to someone, Sitting quietly after a lunch without alcohol, sitting in a vehicle while stopped in traffic for a few minutes). Individual scores gained from these eight sections are then summed to produce a composite score. A total score of 10 or more is considered as excessive daytime sleepiness (28) . Prior to treatment, there were no significant differences between the two groups in global PSQI scores, ESS scores, age, body mass index (Table 1 ) and spirometry and oxygenation indices (Table 3) . Table 2 Table 3 . Mechanisms by which melatonin exerts its main effects remain largely unknown. Recent evidence indicates that melatonin, when secreted in its physiological dose, is able to interrupt circadian rhythm that maintains insomnolence via a receptor-mediated pathway (22) .
In conclusion, wide range of therapeutic use of melatonin in treatment of sleep disturbances reveals the efficacy of this agent and the potential use of melatonin for improving sleep quality in COPD patients with sleep complaints.
